Charles River Laboratories International (CRL) – Research Analysts’ Weekly Ratings Changes

Charles River Laboratories International (NYSE: CRL) recently received a number of ratings updates from brokerages and research firms:

• 12/15/2025 – Charles River Laboratories International had its price target raised by analysts at Barclays PLC from $210.00 to $215.00. They now have an “overweight” rating on the stock.
• 12/15/2025 – Charles River Laboratories International had its price target raised by analysts at JPMorgan Chase & Co. from $165.00 to $190.00. They now have a “neutral” rating on the stock.
• 12/15/2025 – Charles River Laboratories International was upgraded by analysts at Bank of America Corporation from a “neutral” rating to a “buy” rating. They now have a $225.00 price target on the stock.
• 12/13/2025 – Charles River Laboratories International was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/1/2025 – Charles River Laboratories International was given a new $185.00 price target on by analysts at Morgan Stanley.
• 11/17/2025 – Charles River Laboratories International was given a new $200.00 price target on by analysts at Argus.
• 11/17/2025 – Charles River Laboratories International was upgraded by analysts at Argus from a “hold” rating to a “buy” rating.
• 11/11/2025 – Charles River Laboratories International had its price target raised by analysts at Morgan Stanley from $170.00 to $185.00. They now have an “equal weight” rating on the stock.
• 11/10/2025 – Charles River Laboratories International had its price target lowered by analysts at TD Cowen from $205.00 to $197.00. They now have a “buy” rating on the stock.
• 11/8/2025 – Charles River Laboratories International was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/6/2025 – Charles River Laboratories International was upgraded by analysts at Baird R W from a “hold” rating to a “strong-buy” rating.
• 11/6/2025 – Charles River Laboratories International had its price target raised by analysts at JPMorgan Chase & Co. from $160.00 to $165.00. They now have a “neutral” rating on the stock.
• 11/6/2025 – Charles River Laboratories International had its price target raised by analysts at Barclays PLC from $195.00 to $210.00. They now have an “overweight” rating on the stock.
• 11/6/2025 – Charles River Laboratories International was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating. They now have a $199.00 price target on the stock, up previously from $178.00.
• 10/23/2025 – Charles River Laboratories International was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 10/17/2025 – Charles River Laboratories International had its price target raised by analysts at Mizuho from $155.00 to $174.00. They now have a “neutral” rating on the stock.

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).